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ABSTRACT   
We report the feasibility of tumor detection and delineation in vivo using multimode optical imaging of targeted gallium 
corrole (HerGa). HerGa is highly effective for targeted HER2+ tumor elimination in vivo, and it emits intense 
fluorescence. These unique characteristics of HerGa prompted us to investigate the potential of HerGa for tumor 
detection and delineation, by performing multimode optical imaging ex vivo and in vivo; the imaging modes included 
fluorescence intensity, spectral (including ratiometric), lifetime, and two-photon excited fluorescence, using our custom-
built imaging system. While fluorescence intensity imaging provided information about tumor targeting capacity and 
tumor retention of HerGa, ratiometric spectral imaging offered more quantitative and specific information about HerGa 
location and accumulation. Most importantly, the fluorescence lifetime imaging of HerGa allowed us to discriminate 
between tumor and non-tumor regions by fluorescence lifetime differences. Finally, two-photon excited fluorescence 
images provided highly resolved and thus topologically detailed information around the tumor regions where HerGa 
accumulates. Taken together, the results shown in this report suggest the feasibility of tumor detection and delineation by 
multimode optical imaging of HerGa, and fluorescent chemotherapy agents in general. Specifically, the multimode 
optical imaging can offer complementary and even synergetic information simultaneously in the tumor detection and 
delineation by HerGa, thus enhancing contrast. 
Keywords: Multimode optical imaging, two-photon excitation, spectral imaging, fluorescence lifetime imaging 
microscopy (FLIM), tumor targeted corrole, tumor detection. 
 
 
1. INTRODUCTION  
Breast cancer is one of most common cancers occurring in women.  For several decades, although many treatment and 
detection methods for this challenging cancer have been developed, the mortality rate from the breast cancer still 
remains high (1, 2). Recently, we reported a novel molecular construct for HER2+ breast cancer chemotherapy, a tumor-
targeted gallium corrole (HerGa), formed by complexing of a sulfonated gallium corrole (S2Ga) and a recombinant 
tumor-targeting cell penetrating protein, HerPBK10 (3). Our report showed that HerGa is highly effective for both tumor 
detection and treatment in an animal model of HER2+ breast cancer, which is a more aggressive type of breast cancer, 
less responsive to standard interventions (4). In the study, fluorescence intensity imaging could validate the tumor-
targeting capability of HerGa in vivo and ex vivo. Furthermore, the fluorescence intensity difference by HerGa between 
in tumors and normal regions enabled discriminating between them. However, the non-homogeneous accumulation of 
HerGa in vivo and significant background signals, which are produced by the blue light used for HerGa excitation, 
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resulted in reduced contrast, hindering the quantitative analysis for tumor detection in vivo by fluorescence intensity 
imaging (4).  
Therefore, in order to successfully translate HerGa chemotherapy and tumor detection into the clinic, we felt we needed 
to improve the contrast and the accuracy in the imaging-based monitoring of HerGa for tumor detection and delineation. 
This challenge requires new methods, with improved quantification ability and specificity. In our recent studies, we 
showed that multimode wide-field two-photon optical imaging offers improved discrimination between fluorescence 
from molecules of interest and autofluorescence, yielding higher sensitivity and specificity for in vivo applications (5). In 
addition, the new multimode optical imaging system we developed for small animals can be optimized for various 
applications, and the combined optical imaging using the system yields the increased contrast and synergetic information 
gathering in chemotherapy assessment with higher sensitivity and specificity. Particularly, the system offers a 
comprehensive imaging platform for analyzing kinetic, quantitative, environmental, and other highly-relevant 
information with micro- to macroscopic resolution [Hwang, J. Y., et al., submitted for publication].  
We focused here on multimode optical imaging for tumor detection and delineation by HerGa. We tested whether 
multimode optical imaging of HerGa, including fluorescence intensity (6-17), spectral (16, 18-23), lifetime (24-30), and 
two-photon excited fluorescence imaging (31-33), can allow detection/delineation of tumors with better accuracy and 
high specificity. Specifically, we explored the following: 1) the preferential tumor accumulation of HerGa can allow 
detecting tiny tumors (~less 3mm) rather than relatively big tumors used in fluorescence intensity imaging; 2) spectral 
imaging and analysis can provide better quantitative information in tumor detection and delineation after IV 
administration of HerGa; 3) fluorescence lifetime differences of HerGa between tumors and normal tissues enable 
discriminating between these areas; 4) two-photon excited fluorescence imaging can provide high-resolution information 
on HerGa distribution in the tumors, and thus can be utilized for enhanced discrimination between tumors and normal 
tissues. Finally, the suitability and competitive advantages of each imaging mode in the context of improved tumor 
detection and delineation will be discussed.  
 
2. METHODS AND MATERIALS  
2.1 Materials 
HerGa was produced through complexing S2Ga with HerPBK10 at a molar ratio of 30:1 as shown previously (3).  
Female nude mice with implanted MDA-MB-435 human breast tumor were prepared. 1cc of HerGa at a concentration of 
46n moles diluted with phosphate buffer solution (PBS) was injected into intra-vein (IV) of the tail of mice for 
multimode optical imaging (4, 34).  
2.2 Multimode optical imaging system for tumor detection and delineation by HerGa  
In order to perform multimode optical imaging for tumor detection and delineation by HerGa, we used a novel 
multimode optical imaging system that we custom built. This instrument enables, on the same specimen, the 
simultaneous use of various in vivo imaging modes, including one or two photon-excited fluorescence, spectral, 
fluorescence lifetime, intra-vital confocal, and bioluminescence imaging as described previously [Hwang, J. Y., et al., 
submitted for publication]. Each imaging mode has a specific advantage as shown in the Figure 1, such as 
kinetic/dynamic discrimination (fluorescence intensity), quantitative evaluation by segmentation (spectral), functional 
reporting (lifetime), high 3D spatial resolution (two-photon excitation), endoscopic high resolution (intra-vital confocal), 
and high sensitivity (bioluminescence).  
We used four different imaging modes including one and two-photon excitation fluorescence intensity, spectral, and 
lifetime imaging for multimode optical imaging. While we used femto-second (fs) pulsed laser light tuned to 424nm at a 
repetition rate of 80MHz, which was generated by the second harmonic of a fs pulsed laser at 848nm (Mai-Tai Ti-
Sapphire laser, Spectra-Physics), for one-photon excitation of HerGa, we used 100fs pulsed laser light at 848nm for two-
photon excitation of HerGa. In the fluorescence intensity imaging, a cooled CCD camera (PIXIS 400, Princeton 
Instruments) was utilized for detection of the fluorescence signals that passed through a bandpass filter (Chroma 
Technology Corp., 620±30nm). In the spectral imaging, we utilized an acousto-optic tunable filter (AOTF) 
(ChromoDynamics) connected with the cooled CCD camera in order to do sequential spectral selection of emission 
fluorescence from the specimen. A 500nm longpass filter was placed in front of the AOTF to reject the excitation light. 
10 sequential images were here recorded within the spectral range of 500nm to 680nm (step size: 20nm and bandwidth: 
10nm) before and after HerGa intra-tumor injection, for construction of reference spectral signatures, and then spectral 
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signatures of autofluorescence and HerGa fluorescence were generated from the band-sequential images of a mouse by 
using our custom software (19).  
 
 
Fig. 1. Imaging modes in multimode optical imaging system and specific features recommending each mode. 
After that, using these reference spectral signatures, spectral classification for the sequential mouse images obtained after 
HerGa IV injection was performed using a spectral similarity measure based on Euclidean distance calculation, which 
we developed as a plug-in program for Image J (19). On the other hand, we utilized an ultra-fast time-gated camera 
(LaVision, PicoStar HR) for fluorescence lifetime detection, and then a single exponential decay fitting method for the 
fluorescence lifetime analysis (35). Finally, for two-photon excited fluorescence detection, a 60x Nikon objective with 
numerical aperture, 1.4 was utilized. The detected fluorescence signals were recorded in a photmuliplier tube 
incorporated in the scanning two-photon imaging set-up, and then two-photon images were constructed by an image 
reconstruction program we developed. In this in vivo imaging study, in order to minimize motion artifacts, we used a 
gated anesthesia system with a mixture of oxygen and isoflurane.  
 
3. RESULTS AND DISCUSSION 
3.1 Multimode optical imaging for tumor detection and delineation by HerGa 
  3.1.1. Fluorescence intensity imaging  
In a previous report, we have already shown HER2+ tumor targeting capability of HerGa, establishing that HerGa 
specifically accumulates in the tumors, thus enabling their detection (size: ~ 10mm) by HerGa fluorescence difference 
between the tumor and normal regions (4). We here explored whether the preferential accumulation of HerGa in the 
tumors allows detecting much smaller tumors (~less 3mm). We acquired fluorescence intensity and photographic images 
of mice bearing tumors using our custom built multimode optical imaging system, after HerGa IV injection. Figure 2 
shows the fluorescence intensity [Fig. 2.(A)] and photographic image [Fig. 2.(B)]. HerGa fluorescence from the tumor is 
higher than the fluorescence from adjacent normal regions, thus enabling detection of the tumor location as shown 
previously. Moreover, we observed that the contrast between the tumor and adjacent normal regions increased at the 
later time points compared to the contrast at the early time points after HerGa IV administration. In our previous report, 
we noted that significant amount of HerGa was still retained in tumors at 4 days after its IV injection while no detectable 
amount of HerGa could be seen in normal tissues, particularly the muscle [Hwang, J. Y., and etc al, submitted for 
publication]. The contrast enhancement with time mentioned here may have resulted from better tumor retention of 
HerGa than other normal tissues. This suggests that fluorescence intensity imaging of HerGa allows detecting relatively 
tiny tumors, and that the tumor detection by HerGa fluorescence difference may be better at the later times rather than 
immediately after HerGa IV injection. 
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Fig. 2. Fluorescence intensity image of a mouse that received HerGa: Following IV injection of HerGa, a 
fluorescence intensity image (A, left) and a photographic image (B, right) were obtained (excitation: 424nm and 
emission: 620nm). The arrows indicate tumor locations. 
  3.1.2. Spectral imaging and analysis  
In order to investigate feasibility of spectral imaging and analysis for tumor detection and delineation by HerGa, we 
acquired 10 sequential images within the spectral range of 500nm to 680nm with a step size of 20nm and a bandwidth of 
10nm before and at l day after HerGa administration respectively, and then constructed spectral classified images using a 
program we developed. Figure 3 shows the spectral classified images and reference spectral signatures. In Fig. 3(A), the 
spectral classified image (right) obtained after HerGa administration displays a red-pseudo color across the entire mouse, 
thus yielding low specificity in the discrimination between the tumor and normal regions. Generally, in the typical 
spectral imaging and analysis, we utilized pre-constructed spectral signatures, normalized for spectral classification, thus 
being less dependent on fluorescence intensity. Because of this intensity independence, applying a straightforward 
spectral classification would yield low specificity results in discrimination between tumors and normal regions while 
HerGa administrated IV still exists, delocalized over the entire mouse. Thus, in order to obtain successful outcomes from 
this spectral imaging and analysis for tumor detection and delineation by HerGa, we either need to optimize the 
appropriate timing for spectral image acquisition when HerGa is entirely washed out from other normal regions such as 
skin and muscle rather than tumor regions, or alternatively utilize other classification methods such as ratiometric 
spectral imaging. In our other studies, we observed that while HerGa was still significantly retained in tumors at 4 days 
after IV injection, it was not detected in other tissues, particularly heart, brain, muscle, and etc. In this observation, the 
typical spectral imaging and analysis provided quantitative discrimination between HerGa and autofluorescence, with 
high specificity. This indicates that the typical spectral imaging and analysis can be also useful for quantitative tumor 
detection and delineation by HerGa, under the optimized circumstances. Moreover, the ratiometric spectral imaging we 
developed also enables quantitative discrimination between tumors and other regions with high sensitivity while HerGa 
persists in other regions. Taken together, all the results suggest that the spectral imaging and analysis may have a 
potential for quantitative tumor detection and delineation by HerGa with high specificity, but the use of an appropriate 
methodology and that optimized imaging parameters/circumstances are required for successful outcomes.    
 
Fig. 3. Spectrally classified image of a mouse that received HerGa IV injection: (A) spectrally classified 
images were acquired using typical spectral imaging and analysis before (left) and at 1 day after HerGa IV 
injection (right).  (B) spectral signatures of autofluorescence and HerGa. Red: HerGa, Green: autofluorescence. 
The arrow indicates tumor location.  
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  3.1.3. Fluorescence lifetime imaging  
We performed fluorescence lifetime imaging of a mouse that received HerGa via IV injection in order to investigate the 
feasibility that tumor detection and delineation can be achieved by fluorescence lifetime difference mapping of HerGa in 
tumors and normal regions. For fluorescence lifetime imaging, a total of 25 images were acquired within 0 to 4800ps 
with a time step of 200ps, and then a fluorescence lifetime image was constructed using a first-order exponential decay 
fitting method. Figure 4 shows the fluorescence lifetime image and its lifetime histogram obtained at the 4th day after 
HerGa IV administration. The fluorescence lifetimes of HerGa accumulated in tumor regions are somewhat higher than 
in non-tumor regions as shown in Fig. 4(A). Moreover, the histogram of fluorescence lifetimes in tumor regions has a 
greater population at 2.0ns than in non-tumor regions. In our other study, we performed multimode optical imaging of 
HerGa ex vivo with the tumors and the specific organs extracted from this mouse and in vivo while tumor sites and the 
adjacent regions were exposed after HerGa injection. That report showed that fluorescence lifetimes of HerGa in the 
tumors are significantly higher that those in liver ex vivo as well as the fluorescence lifetimes of HerGa in the exposed 
tumors in vivo were higher than those in the exposed adjacent normal regions. The results shown in this paper have a 
good agreement with our previous results, even though the fluorescence lifetime differences of HerGa in tumors and 
other regions are somewhat less than those in isolated organs/tissues. Here it is important to mention that the difference 
of the fluorescence lifetime values of HerGa in tumor and non-tumor regions may become greater if the skin is removed 
since the fluorescence lifetime values we obtained are the average values from skin, tumor, and muscle. These results 
suggest the fluorescence lifetime imaging of HerGa may have potential as a method for tumor detection and delineation. 
In addition, the fluorescence lifetime imaging of HerGa may reflect the micro-environmental status around HerGa since 
the construct’s fluorescence is dependent on surrounding acidity and probably oxygen. Tumor regions are typically more 
acidic and hypoxic than normal tissues. Thus, the fluorescence lifetime difference of HerGa between the tumors and 
normal regions may result from more acidic and hypoxic environment of tumors. This, of course, requires further 
studies. 
 
Fig. 4. Fluorescence lifetime image and a lifetime histogram of the mouse at 4 days after intravenous 
injection of HerGa: (A) Fluorescence lifetime image of the mouse: a total of 25 images were acquired within 0 to 
4800ps with a time step of 200ps. Then, a fluorescence lifetime image was constructed through a first-order 
exponential decay fit. (B) Lifetime histograms within the tumor and non-tumor regions selected by a solid and a 
dotted circle.   
  3.1.4. Two-photon excited fluorescence imaging 
We performed two-photon excited fluorescence imaging of intact tumors of a mouse that received HerGa after the tumor 
sites were exposed in order to examine HerGa distribution in the tumors in detail, with high resolution. Figure 5 shows 
the two-photon exited fluorescence image of the tumor. The bright fluorescence signals indicate HerGa presence, 
illustrating with high spatial resolution HerGa specific accumulation. This, in turn, clearly highlights microstructures in 
the tumors [Fig. 5.(A)], but not in normal tissues (muscle) [Fig. 5.(B)]. Thus, this type of imaging may help physician’s 
decision-making in cancer surgical intervention and detection without the need for rapid histopathological analysis of 
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tissues biopsy during surgery. Furthermore, it can be also utilized one of indicators for assessment of chemotherapy 
effectiveness, since the treatment efficacy depends on drug distributions in tumors.  Taken together, this result indicates 
that the two-photon excited fluorescence imaging of HerGa can be utilized as a high resolution imaging tool for tumor 
detection, thus improving the accuracy in tumor detection in addition to fluorescence intensity, spectral, and lifetime 
imaging.  
 
Fig. 5. Two-photon excited fluorescence images of tumors: The images of (A) tumor and (B) muscle were 
acquired using fs pulsed laser at 848nm, an emission filter with 620nm±60nm, Nikon 60x objective. Scale bar: 
50μm.  
4. CONCLUSIONS 
In this paper, we demonstrated the feasibility and advantages of multimode optical imaging of HerGa for tumor 
detection and delineation. While the fluorescence intensity imaging allows validating the tumor specific targeting 
capacity of HerGa, thus enabling very small tumor detection and delineation, typical spectral imaging can offer more 
quantitative and specific information about HerGa location and accumulation, but careful optimization of imaging 
parameters is needed for successful tumor detection. Most importantly, the fluorescence lifetime imaging enables 
discrimination between tumor and non-tumor regions by fluorescence lifetime difference of HerGa, and provides micro-
environmental information in tissues, simultaneously. Finally, two-photon excited fluorescence imaging of HerGa 
provided highly-resolved topological information around the tumor regions, thus allowing us to validate the 
discrimination between tumors and other normal tissues. Taken together, the results suggest the feasibility and superior 
performance of tumor detection and delineation by multimode optical imaging of HerGa. In particular, the combination 
of fluorescence intensity, spectral, lifetime, and two-photon excited fluorescence imaging can provide 
different/complementary information in the tumor identification, location and characterization by HerGa, thus enhancing 
the ability to diagnose early and treat diseased tissues. 
 
5. ACKNOWLEDGEMENTS 
Partial support from the US Navy Bureau of Medicine and Surgery is gratefully acknowledged. This work was partially 
supported by grants from the NIH (R21 CA116014, R01 CA102126, R01 CA129822, and R01 CA140995), the DoD 
(BC050662), the Susan G. Komen Breast Cancer foundation (BCTR0201194), and the Donna and Jesse Garber Award. 
Work at Caltech was supported by NIH DK019038 and the Arnold and Mabel Beckman Foundation. Work at the 
Technion was supported by The Herbert Irving Cancer and Atherosclerosis Research Fund.  
REFERENCES 
[1] C. Lohrisch and M. Piccart, "An overview of HER2," Seminars in Oncology 28(6 Suppl 18), 3-11 (2001). 
[2] M. Colombo, F. Corsi, D. Foschi, E. Mazzantini, S. Mazzucchelli, C. Morasso, E. Occhipinti, L. Polito, D. 
Prosperi, S. Ronchi and P. Verderio, "HER2 targeting as a two-sided strategy for breast cancer diagnosis and 
treatment: Outlook and recent implications in nanomedical approaches," Pharmacol Res 62(2), 150-165 (2010). 
[3] L. K. Medina-Kauwe, M. Maguire, N. Kasahara and L. Kedes, "Non-viral gene delivery to human breast cancer 
cells by targeted Ad5 penton proteins," Gene Therapy 8, 1753-1761 (2001). 
(A) (B) 
Proc. of SPIE Vol. 7902  79020F-6
Downloaded From: http://proceedings.spiedigitallibrary.org/ on 01/03/2017 Terms of Use: http://spiedigitallibrary.org/ss/termsofuse.aspx
  
[4] H. Agadjanian, J. Ma, A. Rentsendorj, V. Valluripalli, J. Y. Hwang, A. Mahammed, D. L. Farkas, H. B. Gray, Z. 
Gross and L. K. Medina-Kauwe, "Tumor detection and elimination by a targeted gallium corrole," Proc Natl Acad 
Sci U S A 106(15), 6105-6110 (2009). 
[5] J. Y. Hwang, S. Wachsmann-Hogiu, V. K. Ramanujan, A. G. Nowatzyk, Y. Koronyo, L. K. Medina-Kauwe, Z. 
Gross, H. B. Gray and D. L. Farkas, "Multimodal wide-field two-photon excitation imaging: characterization of 
the technique for in vivo applications," Biomedical Optics Express 2(2), 356-364 (2011). 
[6] R. M. Hoffman, "In vivo cell biology of cancer cells visualized with fluorescent proteins," Curr Top Dev Biol 7, 
121-144 (2005). 
[7] M. Vooijs, J. Jonkers, S. Lyons and A. Berns, "Noninvasive imaging of spontaneous retinoblastoma pathway-
dependent tumors in mice," Cancer Res 62(6), 1862-1867 (2002). 
[8] R. Paulmurugan, T. F. Massoud, J. Huang and S. S. Gambhir, "Molecular imaging of drug-modulated protein-
protein interactions in living subjects," Cancer Res 64(6), 2113-2119 (2004). 
[9] C. H. Contag, "In vivo pathology: seeing with molecular specificity and cellular resolution in the living body," 
Annu Rev Pathol 2, 277-305 (2007). 
[10] X. Chen, P. S. Conti and R. A. Moats, "In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain 
tumor xenografts," Cancer Res 64(21), 8009-8014 (2004). 
[11] B. W. Rice, M. D. Cable and M. B. Nelson, "In vivo imaging of light-emitting probes," J Biomed Opt 6(4), 432-
440 (2001). 
[12] R. M. Hoffman, "Imaging tumor angiogenesis with fluorescent proteins," Apmis 112(7-8), 441-449 (2004). 
[13] C. H. Contag and M. H. Bachmann, "Advances in in vivo bioluminescence imaging of gene expression," Annu 
Rev Biomed Eng 4, 235-260 (2002). 
[14] K. Yamauchi, M. Yang, P. Jiang, N. Yamamoto, M. Xu, Y. Amoh, K. Tsuji, M. Bouvet, H. Tsuchiya, K. Tomita, 
A. R. Moossa and R. M. Hoffman, "Real-time in vivo dual-color imaging of intracapillary cancer cell and nucleus 
deformation and migration," Cancer Res 65(10), 4246-4252 (2005). 
[15] M. Bouvet, J. Wang, S. R. Nardin, R. Nassirpour, M. Yang, E. Baranov, P. Jiang, A. R. Moossa and R. M. 
Hoffman, "Real-time optical imaging of primary tumor growth and multiple metastatic events in a pancreatic 
cancer orthotopic model," Cancer Res 62(5), 1534-1540 (2002). 
[16] D. L. Farkas and D. Becker, "Applications of spectral imaging: detection and analysis of human melanoma and its 
precursors," Pigment Cell Res 14(1), 2-8 (2001). 
[17] M. Yang, E. Baranov, P. Jiang, F. X. Sun, X. M. Li, L. Li, S. Hasegawa, M. Bouvet, M. Al-Tuwaijri, T. Chishima, 
H. Shimada, A. R. Moossa, S. Penman and R. M. Hoffman, "Whole-body optical imaging of green fluorescent 
protein-expressing tumors and metastases," Proc Natl Acad Sci U S A 97(3), 1206-1211 (2000). 
[18] R. M. Levenson, D. T. Lynch, H. Kobayashi, J. M. Backer and M. V. Backer, "Multiplexing with multispectral 
imaging: from mice to microscopy," Ilar J 49(1), 78-88 (2008). 
[19] A. Chung, S. Karlan, E. Lindsley, S. Wachsmann-Hogiu and D. L. Farkas, "In vivo cytometry: a spectrum of 
possibilities," Cytometry A 69(3), 142-146 (2006). 
[20] 20. R. M. Levenson and J. R. Mansfield, "Multispectral imaging in biology and medicine: slices of life," 
Cytometry A 69(8), 748-758 (2006). 
[21] R. A. Carano, A. L. Ross, J. Ross, S. P. Williams, H. Koeppen, R. H. Schwall and N. Van Bruggen, 
"Quantification of tumor tissue populations by multispectral analysis," Magn Reson Med 51(3), 542-551 (2004). 
[22] M. V. Macville, J. A. Van der Laak, E. J. Speel, N. Katzir, Y. Garini, D. Soenksen, G. McNamara, P. C. de Wilde, 
A. G. Hanselaar, A. H. Hopman and T. Ried, "Spectral imaging of multi-color chromogenic dyes in pathological 
specimens," Anal Cell Pathol 22(3), 133-142 (2001). 
[23] N. MacKinnon, U. Stange, P. Lane, C. MacAulay and M. Quatrevalet, "Spectrally programmable light engine for 
in vitro or in vivo molecular imaging and spectroscopy," Appl Opt 44(11), 2033-2040 (2005). 
[24] K. M. Hanson, M. J. Behne, N. P. Barry, T. M. Mauro, E. Gratton and R. M. Clegg, "Two-photon fluorescence 
lifetime imaging of the skin stratum corneum pH gradient," Biophys J 83(3), 1682-1690 (2002). 
[25] R. Cubeddu, G. Canti, P. Taroni and G. Valentini, "Time-gated fluorescence imaging for the diagnosis of tumors 
in a murine model," Photochem Photobiol 57(3), 480-485 (1993). 
[26] C. Spriet, D. Trinel, F. Riquet, B. Vandenbunder, Y. Usson and L. Heliot, "Enhanced FRET contrast in lifetime 
imaging," Cytometry A 73(8), 745-753 (2008). 
[27] H. J. Lin, P. Herman and J. R. Lakowicz, "Fluorescence lifetime-resolved pH imaging of living cells," Cytometry 
A 52(2), 77-89 (2003). 
Proc. of SPIE Vol. 7902  79020F-7
Downloaded From: http://proceedings.spiedigitallibrary.org/ on 01/03/2017 Terms of Use: http://spiedigitallibrary.org/ss/termsofuse.aspx
  
[28] S. Murata, P. Herman, H. J. Lin and J. R. Lakowicz, "Fluorescence lifetime imaging of nuclear DNA: effect of 
fluorescence resonance energy transfer," Cytometry 41(3), 178-185 (2000). 
[29] R. Cubeddu, G. Canti, A. Pifferi, P. Taroni and G. Valentini, "Fluorescence lifetime imaging of experimental 
tumors in hematoporphyrin derivative-sensitized mice," Photochem Photobiol 66(2), 229-236 (1997). 
[30] E. Gratton, S. Breusegem, J. Sutin, Q. Ruan and N. Barry, "Fluorescence lifetime imaging for the two-photon 
microscope: time-domain and frequency-domain methods," J Biomed Opt 8(3), 381-390 (2003). 
[31] W. Denk, J. H. Strickler and W. W. Webb, "Two-photon laser scanning fluorescence microscopy," Science 
248(4951), 73-76 (1990). 
[32] G. H. Patterson and D. W. Piston, "Photobleaching in two-photon excitation microscopy," Biophys J 78(4), 2159-
2162 (2000). 
[33] G. Chirico, F. Cannone, G. Baldini and A. Diaspro, "Two-photon thermal bleaching of single fluorescent 
molecules," Biophys J 84(1), 588-598 (2003). 
[34] H. Agadjanian, J. J. Weaver, A. Mahammed, A. Rentsendorj, S. Bass, J. Kim, I. J. Dmochowski, R. Margalit, H. 
B. Gray, Z. Gross and L. K. Medina-Kauwe, "Specific delivery of corroles to cells via noncovalent conjugates 
with viral proteins," Pharmaceutical Research 23(2), 367-377 (2006). 
[35] S. D. Foss, "A method of exponential curve fitting by numerical integration," Biometr 26, 815-821 (1970). 
Proc. of SPIE Vol. 7902  79020F-8
Downloaded From: http://proceedings.spiedigitallibrary.org/ on 01/03/2017 Terms of Use: http://spiedigitallibrary.org/ss/termsofuse.aspx
